Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of frontal fibrosing alopecia with microneedling and photodynamic therapy using 5-aminolevulinic acid
2023-506974-11-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jan 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in frontal fibrosing alopecia (FFA), sponsored by Oslo University Hospital. Primary endpoint: Primary: Reduction of combined erythema and hyperkeratosis score at week 32. Planned start Jan 2024; status: authorised.
02
Drugs
methyl aminolevulinate
03
Conditions
frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on 2023-506974-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506974-11-00.